Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis

被引:1
|
作者
Frederiksen, B [1 ]
Koch, C [1 ]
Hoiby, N [1 ]
机构
[1] UNIV COPENHAGEN, NATL HOSP, DEPT CLIN MICROBIOL, COPENHAGEN, DENMARK
关键词
cystic fibrosis; Pseudomonas aeruginosa; treatment; colistin; ciprofloxacin; prevention; pulmonary function; epidemiology; natural history;
D O I
10.1002/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Chronic pulmonary infection with Pseudomonas aeruginosa (PA) develops in most patients with cystic fibrosis (CF) and is associated with a poor prognosis, Much effort has been directed toward treating the chronic infection, but it is almost impossible to eradicate it once established; therefore, prevention is preferable. Since 1989 CF patients at the Danish CF Center in Copenhagen have been treated with an intensive three-step-protocol consisting of colistin inhalations and oral ciprofloxacin at the time of initial PA colonization. This study compares 48 patients treated according to this intensive protocol with 43 historic controls, The study was carried out over 44 months and included 218 patient-years. Only 16% of the treated patients developed chronic PA infection after 3 1/2 years compared with 72% of the control patients (Kaplan Meier estimate, P < 0.005, log rank test). This indicates that aggressive treatment prevented or delayed chronic PA infection in 78% of the patients for 3 1/2 years. Furthermore, aggressive treatment maintained or increased pulmonary function (forced vital capacity and forced expiratory volume in 1 second in percent of predicted values) during the year after inclusion compared with the control group, in which pulmonary function declined (P < 0.01, Mann-Whitney test). Although some of the treated patients eventually developed chronic PA infection, these patients had significantly better pulmonary function at the onset of chronic PA infection compared with control patients (P < 0.001, Mann-Whitney test). When the different steps in the intensive three-step-protocol were analyzed, there was a trend suggesting that 3 months of high-dose treatment with colistin inhalation and oral ciprofloxacin produced the best results in terms of postponement or prevention of chronic PA infection (P < 0.05). (C) 1997 Wiley-Liss, Inc.
引用
收藏
页码:330 / 335
页数:6
相关论文
共 50 条
  • [41] The effect of Pseudomonas aeruginosa eradication regimens on chronic colonization and clinical outcomes in pediatric patients with cystic fibrosis
    Buyuksahin, Halime Nayir
    Yalcin, Ebru
    Emiralioglu, Nagehan
    Hazirolan, Gulsen
    Tural, Dilber Ademhan
    Ozsezen, Beste
    Sunman, Birce
    Guzelkas, Ismail
    Dogru, Deniz
    Ozcelik, Ugur
    Kiper, Nural
    PEDIATRICS INTERNATIONAL, 2022, 64 (01)
  • [42] Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization
    Munck, A
    Bonacorsi, S
    Mariani-Kurkdjian, P
    Lebourgeois, M
    Gérardin, M
    Brahimi, N
    Navarro, J
    Bingen, E
    PEDIATRIC PULMONOLOGY, 2001, 32 (04) : 288 - 292
  • [43] Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence
    Hamed, Kamal
    Debonnett, Laurie
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2017, 11 (05) : 193 - 209
  • [44] Nebulized colistin versus tobramycin in the treatment of chronic Pseudomonas colonization in cystic fibrosis patients
    Quintana-Gallego, Esther
    Luis Lopez-Campos, Jose
    Calero, Carmen
    Javier Dapena, Francisco
    MEDICINA CLINICA, 2014, 142 (02): : 59 - 63
  • [45] Inhaled antibiotics for the treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients: challenges to treatment adherence and strategies to improve outcomes
    Bodnar, Reka
    Meszaros, Agnes
    Olah, Mate
    Agh, Tamas
    PATIENT PREFERENCE AND ADHERENCE, 2016, 10 : 183 - 193
  • [46] Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review
    M. C. Gaspar
    W. Couet
    J.-C. Olivier
    A. A. C. C. Pais
    J. J. S. Sousa
    European Journal of Clinical Microbiology & Infectious Diseases, 2013, 32 : 1231 - 1252
  • [47] Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis
    Antoniu, Sabina
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2015, 13 (07) : 897 - 905
  • [48] Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis
    Anna S. Tai
    Laura J. Sherrard
    Timothy J. Kidd
    Kay A. Ramsay
    Cameron Buckley
    Melanie Syrmis
    Keith Grimwood
    Scott C. Bell
    David M. Whiley
    BMC Pulmonary Medicine, 17
  • [49] Prevalence of antibiotic resistance of Pseudomonas aeruginosa in cystic fibrosis infection: A systematic review and meta-analysis
    Bonyadi, Parisa
    Saleh, Narjes Tehrani
    Dehghani, Mohadeseh
    Yamini, Mahsa
    Amini, Kumarss
    MICROBIAL PATHOGENESIS, 2022, 165
  • [50] Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection
    Steinkamp, Gratiana
    Schmitt-Grohe, Sabina
    Doering, Gerd
    Staab, Doris
    Pfruender, Dietmar
    Beck, Gudrun
    Schubert, Ralf
    Zielen, Stefan
    RESPIRATORY MEDICINE, 2008, 102 (11) : 1643 - 1653